Trending Now
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
Ophthalmology Industry Consolidation Accelerates as MyEyeDr and Glaukos Announce Strategic Deals
Breaking News
Surgical innovation in dry eye disease: Salivary gland transplant
Ağustos 27, 2025
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
OCT changes with low-level red light therapy for myopia in children
Ağustos 26, 2025
Alcon presenting at APACRS 2025
Ağustos 21, 2025
Breaking News
Popular Now
AAO 2026 Highlights Hospital Ophthalmology Coverage Gaps and Growing Reimbursement Pressures
Access to hospital-based eye care and reimbursement were policy topics at the…
Inflammasome Therapeutics’ Kamuvudine K8 Reduces Geographic Atrophy Lesion Growth by 54% in Phase 2 Study
Phase 2 data for kamuvudine K8, an investigational inflammasome-directed treatment from Inflammasome…
Ophthalmology Industry Consolidation Accelerates as MyEyeDr and Glaukos Announce Strategic Deals
Two transactions announced in September and October 2026 show capital moving through…
GenSight Biologics Publishes GS030 PIONEER Optogenetic Therapy Results in the New England Journal of Medicine
GenSight Biologics and the Quinze-Vingts National Ophthalmology Hospital in Paris announced on…
Collaborate With Us
Join forces with Ophthalmology News to reach a global community of eye care professionals. Whether you want to contribute an article, share research, or explore partnership opportunities, we’d love to hear from you.
Editor Choice
Kodiak Sciences’ Tarcocimab Meets Noninferiority Endpoint Versus Aflibercept in Phase 3 DAYBREAK Trial in Wet AMD
Kodiak Sciences announced on 28 September 2026 that Zenkuda (tarcocimab tedromer), an…
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program…
When Mites Meet Their Match: Empowering Patients With Targeted Treatment for Demodex Blepharitis | Ophthalmology Times
Thanks for your interest in this podcast. Please read this important program…
International Glaucoma Symposium highlights the meeting point of practice and technology | Ophthalmology Times
The 2nd International Glaucoma Symposium underscores how AI and advanced imaging are…
MRI study links glymphatic system dysfunction to idiopathic intracranial hypertension | Ophthalmology Times
(Image Credit: AdobeStock/littlewolf1989) A press release from Mass General Brigham, Boston, reported…
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials | Ophthalmology Times
FDA approval of YUVEZZI marks the first dual-agent, daily eye drop option…
FDA Type C meeting supports phase 2b/3 pathway for urcosimod in neuropathic corneal pain | Ophthalmology Times
(Image Credit: AdobeStock/OlegKachura) Editor’s Note: This content was generated with the assistance of…
FDA approves NDA labeling supplement allowing re-administration of iDose TR | Ophthalmology Times
The US Food and Drug Administration has approved an NDA labeling supplement…
Belite Bio completes enrollment in phase 2/3 DRAGON II trial for STGD1 | Ophthalmology Times
(Image Credit: AdobeStock/khunkornStudio) Belite Bio has completed enrollment in its phase 2/3…
Worth Reading
Meeting expectations with evolving technology
Ağustos 26, 2025
/ Patient Education, Research & Studies, Technology & Innovation, Treatments & Surgery
Unpacking high-yield ophthalmology tips and clinical pearls, with Nicole Bajic, MD
Ağustos 26, 2025
/ Industry News, Patient Education, Research & Studies, Treatments & Surgery
Possible protective role of cannabis in preventing postoperative proliferative vitreoretinopathy after retinal detachment repair
Ağustos 26, 2025
/ Patient Education, Research & Studies
Next-generation IOLs advance complex cataract care
Ağustos 26, 2025
/ Patient Education, Research & Studies, Treatments & Surgery
Subscribe Now
Enter your email address below and subscribe to our newsletter